I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

Diversified Royalty Acquired the Trademarks and Some Other Intellectual Property Used by Cheba Hut Franchising for $36M and Additional Consideration; Adds Ninth Royalty Stream and Second Based in U.S.

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...